Close Menu
Home » The Scan » Down the Pike

Down the Pike

May 19, 2009

Chris at R&D Directions Insider blog spoke with both Merck's Alan Sachs and Amgen's Sean Harper down at the BIO meeting in Atlanta. Sachs is a VP of RNA Therapeutics and tells Chris that Merck isn't focusing on the delivery of RNA-based drugs but instead is looking whether RNA-based drugs make be safely taken for a chronic condition.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

After Your Number

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Not Quite How It Works

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Research, But Not in Name

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

Science Finds Support for Gene Drives Depends on Species Targeted, Ability to Control Drive; More

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.